Although ion channels hold great promise in targeted cancer therapy, they still face significant challenges, of which personalized therapy, drug treatment sensitivity, and off-target toxicity of targeted potassium channel drugs are still poorly studied (2). This evidence concerns the gene KCNA3 and cancer.